# EnginZyme

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enginzyme

- Industry: Materials
- Headquarters: Stockholm, Sweden
- Website: www.enginzyme.com
- Total disclosed funding: $35M
- Latest round: Series B (Dec 19, 2022)
- Investors on record: 6

## About

Based in Sweden, EnginZyme AB specializes in developing biomanufacturing solutions through patented enzyme immobilization technology, facilitating sustainable practices in chemical production. EnginZyme AB, founded in 2014 in Stockholm, Sweden, focuses on innovative biomanufacturing solutions. The company was established by Karim Cassimjee, Robin Chatterjee, and Samuel Härgestam. In September 2026, EnginZyme AB raised approximately SEK 75 million in venture funding from new investors Lotus One Investment and Valquest Partners, with participation from returning investors Navigare Ventures, Sofinnova Partners, Industrifonden, and ALMI Invest. Other unspecified investors also participated in the round.
EnginZyme specializes in the development of innovative biomanufacturing solutions utilizing its patented enzyme immobilization technology, enabling the creation of bespoke biocatalysts. These products support sustainable manufacturing across the chemical, pharmaceutical, and food industries, focusing on reducing energy consumption and greenhouse gas emissions.

## Funding rounds

- Series B, Dec 19, 2022, $22M — Sofinnova Partners, SEB Venture Capital, Industrifonden, ALMI Invest, Bunge Ventures, Navigare Ventures
- Series A, Feb 11, 2021, $5.6M — SEB Venture Capital, Industrifonden
- Series A, Apr 22, 2020, $6.9M — Sofinnova Partners

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B
- SEB Venture Capital (https://capitalatlas.ai/funds/seb-venture-capital) — Series A, Series B
- Industrifonden (https://capitalatlas.ai/funds/industrifonden) — Series A, Series B
- ALMI Invest — Series B
- Bunge Ventures — Series B
- Navigare Ventures (https://capitalatlas.ai/funds/navigare-ventures) — Series B